CVS Health Stock’s Next Leg Sits In Aetna’s Unfinished Margin Repair

Management has raised its full-year earnings outlook twice, and the segment doing most of the lifting is still short of its own target margin.

CVS Health (CVS) stock has returned 0.2% over the past three months while the S&P 500 returned 4.6%, a strange pause for a stock up 50.6% over the trailing twelve months. The earnings power underneath the stock did not pause. The upside case rests on one repair still in progress through deliberate management actions: the margin recovery at Aetna, its health benefits business.

Aetna’s Turnaround Kept Delivering Through June

The starting point matters: on the first-quarter call in May, the company said its Medicare business improved significantly in 2025 and still generated an adjusted operating loss. Year-over-year improvement in adjusted operating income at Aetna was more than $1 billion through the March quarter and more than $2 billion through the June quarter. That is one lever measured twice, moving one way. The mechanism management describes is unglamorous: two years of deliberate coordinated actions at Aetna, progress in the geographic footprint and product mix, top Medicare Star Ratings (which drive performance bonus payouts), and a Medicare business the company now says is ahead of expectations.

The Guidance Raise Is Bigger Than Its One-Time Help

Building on that momentum, full-year 2026 guidance for Health Care Benefits adjusted operating income was raised by more than $1 billion in a single quarter. Roughly $500 million of that is not core: a net risk adjustment update and prior-year development. The rest is first-half operating performance, and the company says it flowed only part of that outperformance into the raise.

Enterprise adjusted EPS guidance now reads $7.90 to $8.10 after a $0.60 raise, the second raise of 2026, and the cash flow from operations outlook moved to at least $11.5 billion, up $2 billion. Rising cash alongside rising earnings is one of the qualities the Trefis High Quality Portfolio insists on in its holdings. On a segment previously guided around $5 billion in annual operating income, adding $1 billion represents a roughly 20% jump—demonstrating how heavily this single segment is powering enterprise earnings.

Caremark’s 2027 Headwinds

The bill arrives in 2027. The company has flagged a headwind in its Pharmacy Services business from 340B, a program that supports care for underserved populations, and expects membership declines at Caremark, with client retention trending slightly below its own historical rate but closer to industry norms. Its specialty pharmacy business and a robust generic portfolio in 2027 are the stated offsets, and management has not put a number on the 340B pressure.

The Floor Management Published A Quarter Early

The upside is not a new product or a new market; it is an insurance margin still climbing back, and management describes a pathway back to target margins over the next couple of years, with about 75% of the group Medicare Advantage book already renewed at 2027 pricing. The one number that tests it was published a quarter earlier than usual: adjusted EPS of at least $8.44 in 2027, about 13% growth off an adjusted baseline of $7.46, which strips out $0.54 per share in prior-year development, net risk adjustments, and prior-year items in the exited individual exchange business from the $8.00 guidance midpoint. That floor rises if Aetna’s gains keep outrunning the Caremark bill. This stock has gained more than 30% in under two months six separate times since 2020 and sits about 14% below its 52-week high. As a group, companies whose guidance keeps climbing are worth watching.

One Insurance Margin Is Not A Portfolio

The recovery at Aetna may play out exactly as management describes, and the outcome would still rest on one segment inside one company. The Trefis High Quality Portfolio spreads that dependence across a rules-based basket rather than a single margin line. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.